This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e135. Learning Objective-Upon completion of this activity, successful learners will be able to identify risk factors associated with post-ERCP pancreatitis and ways of minimizing its occurrence.
T he most common and dreaded complication of endoscopic retrograde cholangiopancreatography (ERCP) is pancreatitis, which has an incidence of more than 15% in high-risk patients. [1] [2] [3] Recognition of risk factors for post-ERCP pancreatitis (PEP) is important for both the interventional endoscopist, and for physicians who refer patients for ERCP (Table 1) . However strong the indication for ERCP, recognition of medications that help to minimize the incidence of PEP ( Table 2 ) and cognizance of techniques that both increase and decrease the incidence of PEP are essential. In this review, we evaluate the medications and techniques that can influence, and potentially prevent, PEP.
Pharmacologic Prevention

Anti-Inflammatory Drugs
Regardless of the inciting cause of acute pancreatitis, the subsequent elaboration of local and systemic proinflammatory mediators is central to the development of systemic inflammatory response syndrome and serious end-organ injury. 4 This understanding presents a number of suitable targets for pharmacoprevention in the scenario in which the initial injury can be defined easily, as in PEP.
Nonsteroidal Anti-Inflammatory Drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are potent inhibitors of cyclooxygenase and phospholipase A2. Between 2003 and 2008 there were 4 independently conducted small trials of either rectally administered diclofenac (2 studies) 5, 6 or indomethacin (2 studies), 7, 8 which suggested the potential for benefit. A single study investigating the oral administration of diclofenac was negative. 9 All 4 of the studies using the rectal route of administration were included in a meta-analysis, with a total of 912 patients. This study found a relative risk (RR) of 0.36 (95% confidence interval [CI], 0.22-0.60) in favor of rectal NSAIDs for the prevention of PEP. 10 A complementary meta-analysis of the same data suggested a reduction in both mild and moderate to severe PEP. 11 These data led the European Society for Gastrointestinal Endoscopy to support the use of rectal NSAIDs for the prevention of PEP. 12 In 2012, Elmunzer et al 13 published a multicenter, double-blind, placebo-controlled trial of rectal indomethacin (2 suppositories of 50 mg given immediately after ERCP) that included a total of 602 patients. The results of this study were highly significant and in favor of indomethacin because PEP developed in 16.9% of control patients and in only 4.4% of those who received indomethacin (P ¼ .005). In addition, moderate-tosevere pancreatitis was found to be almost twice as common in control patients (8.8% vs 4.4%; P ¼ .03).
Although unquestionably well designed, this study was criticized for its inclusion of high-risk patients, many of whom had suspected sphincter of Oddi dysfunction (SOD). More than half of the included patients had sphincter hypertension at manometry before biliary sphincterotomy. In subgroup analysis, there was a trend toward benefit for patients without SOD (8.5% vs 20.0%; P ¼ .11), although this was not statistically significant. The investigators argued that this finding was likely of clinical significance, and the failure to achieve significance was owing to the relatively small fraction of patients without suspected SOD (only 107 of 602).
Since the publication of this landmark study, 13 there have been 2 additional meta-analyses performed that included these data. 14, 15 Both showed that the use of NSAIDs significantly decreased the overall incidence of PEP.
The remaining question, in our view, is to determine what place NSAIDs occupy in the framework of other preventative strategies for PEP, including pancreatic stent placement. This question was partly addressed by an exploratory post hoc analysis by Elmunzer et al, 16 which suggested that NSAIDs may have been efficacious regardless of the placement of a pancreatic duct (PD) stent. More recently, a network meta-analysis published in Clinical Gastroenterology and Hepatology reported that NSAIDs in fact may be more efficacious than PD stent placement, although this question remains unsettled. 17 It is notable that rectal NSAIDs are extremely inexpensive. A cost-benefit analysis of indomethacin monotherapy suggested an average per-patient savings of $1472 when compared with stent placement. 16 In an environment increasingly conscious of the escalating cost of health care, these savings warrant serious consideration.
It is our practice to administer a single 100-mg dose of indomethacin, via a rectal route, immediately after ERCP, to any patient who might have some increased risk for PEP, unless there is an absolute contraindication, such as in patients with NSAID allergies.
Corticosteroids. Early studies using corticosteroids, which act principally through the inhibition of phospholipase A2, showed some success in reducing PEP. 18 However, no benefit in the reduction of PEP was observed when larger randomized patient samples were analyzed. 19, 20 Other anti-inflammatory agents that have been unsuccessfully tested include pentoxifylline, 21 recombinant human interleukin 10, 22 and low-dose Published trials showed no statistical advantage over placebo, or increased incidence of PEP. b Some RCTs showed a benefit but other RCTs or meta-analyses did not. Insufficient published experience to define a clear role in PEP. c Multiple RCTs and/or meta-analyses showed a consistent and significant reduction in the incidence or severity of PEP. unfractionated heparin. 23 We do not routinely administer corticosteroids to patients undergoing ERCP for the purpose of reducing the risk of PEP.
Sphincter Relaxants
Using a mechanism that is conceptually analogous to PD placement, several agents aimed at promoting PD drainage via papillary relaxation have been investigated with respect to PEP. These include secretin (which is also a regulatory hormone and is described in the following section), nitrates, nifedipine, botulinum toxin, lidocaine, 24 and epinephrine. 25 Nitrates. In a low-risk population of 186 subjects, 2 mg of sublingual glyceryl trinitrate (nitroglycerin [NTG]) administered 5 minutes before ERCP initially was shown to reduce the overall incidence of PEP significantly from 17.7% to 7.8%. 26 In subsequent series, both the transdermal [27] [28] [29] and intravenous 30 routes of NTG administration have been evaluated with mixed results.
In an attempt to clarify the available data, a metaanalysis of 5 randomized controlled trials (RCTs) that included 1660 patients was conducted. This publication showed a RR reduction of 0.61 (95% CI, 0.44-0.86) in favor of the administration of NTG. This analysis suggested a number-needed-to treat (NNT) of 26 to prevent 1 episode of PEP. Unfortunately, this analysis was limited by significant heterogeneity between individual studies including the route of administration, drug dose, and timing. Although overall in favor of nitrates, the preferred transdermal method of delivery did not confer a significant advantage over placebo. In addition, use of nitrates also was associated with a significant increased risk of both hypotension (RR, 2.25) and headache (RR, 3.64). 31 A separate meta-analysis that included 8 RCTs and 1920 patients showed similar results. 32 At the present time, the use of nitrates for prevention is not recommended. The combination of conflicting data regarding their efficacy, as well as the potential for serious side effects (such as hypotension), makes it difficult to recommend the routine use of nitrates for the prevention of PEP. 33 Nifedipine, lidocaine, epinephrine. Systemic nifedipine, a dihydropyridine thought to promote papillary relaxation through its action on L-type calcium channels, was ineffective in 2 controlled trials. 34, 35 Similarly, neither lidocaine 24 nor epinephrine 25 have been shown to be effective in preventing PEP when sprayed topically on the major papilla.
Botulinum toxin. In a novel approach, two 25-U aliquots (each of 0.25 ml) of botulinum toxin were injected into the pancreatic sphincter in 12 of 26 randomized patients with suspected SOD. All of these subjects had increased basal sphincter pressures and subsequently underwent biliary sphincterotomy. This study failed to show a statistical advantage of botulinum when compared with sham injection (25% vs 43% respective rates of PEP; P ¼ .34), and was terminated early because of the unacceptably high rate of PEP in the control arm receiving saline injection. 36 As such, we do not recommend using medications that might help with papillary sphincter relaxation to prevent PEP at this time.
Regulatory Hormones
Somatostatin/octreotide. The peptide hormone somatostatin (SS), along with its synthetic analogue octreotide, have been investigated extensively for the chemoprophylaxis of PEP. Both of these compounds function by inhibiting the exocrine secretion of the pancreas directly and through the suppression of the complementary actors secretin and cholecystokinin. 37 Despite this physiologic basis, clinical trials using both agents have shown inconsistent and often conflicting results.
A meta-analysis, published in 2007, that included 16 trials compared the administration of SS with controls for the incidence of pancreatitis, hyperamylasemia, and pain. Although pancreatitis occurred in 7.3% of controls compared with 5.3% of patients treated with SS, this difference was not statistically significant. 38 In 2008, a second systematic review that included 15 trials and 2621 patients also did not find any benefit in favor of treatment with octreotide. Similar to the results with SS, pancreatitis occurred in 7.0% of controls compared with 5.5% of treated patients, resulting in a nonsignificant odds ratio (OR) of 0.78 (95% CI, 0.57-1.08). 39 Despite these earlier results, a more recent metaanalysis that included 3818 patients, examined 17 trials of SS or octreotide and suggested that these drugs might prevent PEP when used in bolus fashion (SS) or in sufficient dosages (octreotide). A subgroup analysis of patients in this study showed that these drugs were also more efficacious in cases of PD injection and biliary sphincterotomy. 40 Large-scale studies need to be performed before determining the role of SS and octreotide in the prevention of PEP.
Secretin. Secretin is a biologically active peptide with a primary function of driving pancreatic bicarbonate secretion. Secretin also promotes relaxation of the sphincter of Oddi. 41 In a single-center RCT that included 869 patients, intravenous (IV) administration of secretin showed a significant reduction (8.7% vs 15.1%; P ¼ .004) in the incidence of PEP when compared with controls who received the same volume of IV normal saline. In subgroup analysis, this study showed the greatest efficacy in PEP reduction among patients who underwent biliary sphincterotomy (6 of 129 vs 32 of 142; P < .001). 42 Although compelling, these data were limited to a single-center experience. Furthermore, both the cost and historically limited availability of IV secretin are potential barriers to widespread implementation of this agent for PEP.
Please refer to the Supplementary Materials section for additional information on the role of other hormones, protease inhibitors, and other medication therapies in preventing PEP.
Intravenous Fluid Administration
Given the long-standing interest in the chemoprevention of PEP, it is surprising that the linchpin of therapy for acute pancreatitis has received little attention as a potential preventative (or ameliorative) strategy. DiMagno et al 43 reported in a hypothesis-generating study that greater periprocedural fluid volume was an independent protective factor against moderate to severe PEP. A study by Buxbaum et al 44 included 62 patients randomized in a 2:1 fashion to either aggressive IV hydration with lactated Ringers (3.0 mL/kg/h during ERCP followed by a 20-mL/kg bolus and a 3-mg/kg/h infusion for 8 hours postprocedure) or standard hydration (1.5 mL/kg/h during and for 8 hours postprocedure). Patients in the aggressive hydration group received a median volume of 3.8 L of lactated Ringer's solution compared with 2.2 L in the standard hydration group (P < .001). Risk factors for the development of PEP were similar between patient groups. Notably, PEP occurred only in the standard hydration group (17%) and did not occur in the aggressive hydration group (0%; P ¼ .016).
This study had several limitations. First, the sample size was small and therefore it was underpowered and prone to type I/II errors. Second, the rate of PEP in the control group was higher than expected (at 17%) and the experimental arm had fewer than expected (0%) episodes of pancreatitis. Despite these concerns, post-ERCP intravenous hydration remains a tempting target for future work on preventing PEP.
Endoscopic Retrograde Cholangiopancreatography Techniques and Postprocedural Pancreatitis
As most experienced endoscopists know, medications, sedative or otherwise, are not a substitute for good endoscopic technique. In the following sections, the evidence behind ERCP best practices, as they relate to minimizing the risk of PEP, are discussed.
Use of Pancreatic Duct Stents as Prophylaxis Against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
The ability to place a small-caliber prophylactic PD stent is required for any endoscopist who engages in performing ERCPs. As a general rule, if the pre-ERCP risk of pancreatitis is increased because of the patient's clinical factors or procedural factors (Table 1) , it generally is recommended to attempt to place a prophylactic PD stent.
From numerous studies, it is clear that PD stents reduce the risk and probably the severity of PEP. [45] [46] [47] [48] [49] [50] Mazaki et al 51 conducted a meta-analysis that included 8 studies. In a pooled analysis, 336 patients had PD stent placement and 344 patients formed the control group. PD stent placement was associated with a statistically significant reduction in PEP (RR, 0.32; 95% CI, 0.19-0.52; P < .001). Choudhary et al 52 conducted an even larger meta-analysis that included 8 RCTs (656 subjects) and 10 nonrandomized studies (4904 subjects). Their meta-analysis of the RCTs showed that prophylactic PD stents decreased the odds of PEP (OR, 0.22; 95% CI, 0.12-0.38; P < .01). The absolute risk reduction was 13.3% (95% CI, 8.8%-17.8%). The NNT was only 8. Similar findings also were noted from a metaanalysis of the nonrandomized studies.
However, Freeman et al 53 showed in a multivariate analysis of a study of 225 patients at increased risk for PEP, all of whom had attempted PD stent placement, that unsuccessful pancreatic stent insertion was associated with the highest overall odds of PEP (OR, 16.1; 95% CI, 1.3-200), which was even greater than that for patients with SOD (OR, 3.2; 95% CI, 1.4-7.5) and prior PEP (OR, 3.2; 95% CI, 1.4-7.1). A similar result was shown by Ito et al 54 in a study of ERCP in patients with difficult biliary cannulation. In this study, on multivariate analysis, unsuccessful PD stenting was found to be the only risk factor for PEP (OR, 8.3; 95% CI, 2.3-30). Choksi et al 55 further corroborated the increased risk of PEP associated with failed PD stenting in a post hoc analysis of data from high-risk patients randomized to receive rectal indomethacin or placebo. 13 Failed PD stenting occurred in 7.8% of attempts in this study. Patients who did not receive indomethacin and had failed PD stent placement had a 34.7% rate of PEP, which was significantly greater than the PEP rates in patients in whom PD stenting was not attempted or in whom PD stenting was successful. Interestingly, patients who received indomethacin but also had failed PD stent placement had a 5.3% rate of PEP, which was not statistically different compared with the 2 earlier-mentioned comparison groups. Overall, these studies underscore the need for proper training and experience in ERCP, including comfort in placement of prophylactic PD stents.
PD stents commonly are made of polyethylene, which is sometimes mixed with vinyl or other softer materials, 56 and typically have side holes (Figure 1 ). 57 Although the optimal size and length for a prophylactic PD stent have not been clearly determined, a metaanalysis suggested that 5F stents were superior to 3F stents in preventing PEP. 58 Generally, it is recommended to use a small-caliber plastic stent (3F, 4F, or 5F) that is either short (3-to 4-cm long and does not pass to the genu) or long (stent ends in the pancreatic tail). 59 For endoscopists who preferentially use an 0.035" or 0.025" guidewire, 5F stents are used more commonly because placement of a thinner stent usually requires opening a second, smaller-caliber guidewire (typically an 0.018" wire), which adds cost to the procedure. We recommend that when placing a PD stent as prophylaxis against PEP to use a 5F or smaller plastic stent that is short (4 cm in length, so that it does not cross the genu) and reliably will migrate out of the pancreatic duct within 2 weeks.
Although the data for PD stenting are compelling, it is interesting that a post hoc analysis by Elmunzer et al 16 showed that rectal indomethacin alone appeared to be more effective for preventing PEP than no prophylaxis, prophylactic PD stenting alone, and the combination of indomethacin and prophylactic PD stent placement. Although future RCTs to address this question formally are of utmost importance, it is our current recommendation that in patients at increased risk for PEP, even if PD stenting is successful, strong consideration should be given to concomitant administration of rectal indomethacin.
Guidewire Cannulation Versus Catheter Cannulation and Contrast Opacification
The target for bile duct and main PD cannulation is success in more than 85% of ERCP procedures, as set forth by the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy Taskforce on Quality in Endoscopy. 60 These thresholds were validated by a meta-analysis that found a bile duct cannulation success rate of 89.3% (95% CI, 0.866-0.919) and a pancreatic duct cannulation success rate of 85.0% (95% CI, 0.813-0.886). 61 With respect to selective cannulation of the bile duct, there have been at least 5 high-quality RCTs investigating guidewire (GW) cannulation vs catheter cannulation followed by contrast opacification (CCC) ( Table 3 ). In the past 5 years, 6 RCTs and 1 large prospective study investigated the approaches of GW vs CCC for biliary access. Two studies 62, 63 showed statistically significant improvement in the rate of biliary access by using the GW approach, and a single study reported reduced rates of PEP using the GW approach. 48 However, these studies were heterogeneous and some of the studies included trainees who performed ERCP and other studies did not use prophylactic PD stenting as part of the ERCP procedures. To better address this issue, Tse et al 64 conducted a Cochrane meta-analysis comparing these 2 approaches and included 12 studies in the main analysis investigating PEP rates. In aggregate, there were 1784 patients in the GW-assisted cannulation group and 1666 patients included in the CCC group. Despite significant heterogeneity, unweighted pooled rates of PEP were 3.5% for the GW group and 6.7% for the CCC group. The GW-assisted cannulation technique significantly reduced PEP compared with the contrast-assisted cannulation technique based on an intention-to-treat analysis (RR, 0.51; 95% CI, 0.32-0.82; P ¼ .005). With respect to preventing PEP, the NNT was 31 for the GW group. The GW group also had higher primary cannulation rates (RR, 1.07; 95% CI, 1.00-1.15; P ¼ .05). With respect to improved cannulation success, the NNT was 18 when using the GW technique.
Based on these aggregate data, most expert endoscopists recommend GW cannulation when performing ERCP. There is no good evidence to suggest that one caliber or type of wire is superior to the others in terms of reducing PEP risk.
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Use of Pancreatic Duct Access to Facilitate Difficult Biliary Access
In instances with a floppy papilla or an angulated intrapapillary bile duct, passage of a guidewire can lead to inadvertent pancreatic access, and selective biliary access might not be possible using standard cannulation techniques. In such situations there are several advanced techniques that use a PD wire to facilitate selective biliary cannulation. First, the double-GW technique: the PD wire is left in place, and a second guidewire then is passed via a sphincterotome or catheter and alongside the pancreatic wire, which allows for fluoroscopic reference, straightens the approach to the bile duct, and occupies space in the PD, thereby facilitating biliary cannulation 67, 68 ( Figure 2 ). Second, PD stent placement followed by attempted biliary cannulation, which if not successful then a precut needle-knife (NK) biliary papillotomy can be performed. 68 Third, transpancreatic sphincterotomy or septotomy (TPS) for biliary access, 67,69-71 which can be followed by double-GW biliary cannulation and then PD stenting or, The right column shows an array of soft plastic (combination of polyethylene and vinyl) pancreatic stents (Advanix; Boston Scientific, Natick, MA). In general, 5F stents may be passed over 0.035" and thinner guidewires, 4F stents may be passed over 0.025" and thinner guidewires (although some newer 4F stents can be placed over an 0.035" guidewire), and 3F stents require 0.018" (for most vendors) or 0.021" guidewires, which may be more difficult to use. alternatively, by first placing a PD stent and then attempting biliary cannulation.
Rates of successful biliary access by using each of these advanced techniques are high, typically in the 67%-94% range. 67, 68, 72 More recently, several studies [73] [74] [75] have shown that precut TPS for biliary access is not associated with higher rates of pancreatitis as compared with precut NK papillotomy. Wang et al 73 reported a pancreatitis rate of 11.4% in a TPS group compared with 11.8% in a NK papillotomy group. Catalano et al 74 found a lower pancreatitis rate with TPS (3.4%) as compared with NK papillotomy (11.8%), but this difference was not statistically significant. 75 Finally, a RCT by Yoo et al 67 that compared TPS with the double-GW technique for biliary access in patients with difficult biliary cannulation surprisingly found a significantly higher rate of PEP in the double-GW group (38.2%) as compared with the TPS group (10.8%; P < .011); however, PD stents were not used in this study. In published studies, PEP rates range from 2.4% to 12.5% for TPS. 67, 70, 71, [74] [75] [76] Although the use of PD stenting was heterogeneous in these studies, we do recommend placing a prophylactic PD stent after TPS. In summary, in instances in which attempts at selective biliary access result in repeated PD wire cannulation, we recommend leaving the PD wire in place and using a second wire to attempt biliary access. If not successful, either PD stenting followed by re-attempted biliary access and then NK precutting over the PD stent or precut TPS followed by PD stenting can be used in situations in which biliary access is imperative.
Early Precut Biliary Papillotomy
Precut biliary papillotomy using a NK can be performed freehand or over a PD stent in the case of inadvertent PD cannulation (Figure 3) , as previously described. In earlier prospective nonrandomized studies, 2,77 precutting was associated with an increased risk of pancreatitis. This increased risk of PEP has been Figure 2 . Attempted selective biliary cannulation using a sphincterotome and guidewire resulted in PD access. (A and B) The PD guidewire was left in place, and the sphincterotome was loaded with a second guidewire to re-attempt biliary access. The PD guidewire straightened the ampulla and biliary approach and also served as a fluoroscopic reference. (C) Biliary access was obtained and (D) cholangiography was performed. A biliary sphincterotomy was effected with the pancreatic guidewire in place, (E and F) after which a 5F, 4-cm, single-pigtail, plastic stent was placed into the main PD via the duct of Wirsung. Retrieval balloon sweep in this patient with an abnormal intraoperative cholangiogram was performed. Indomethacin 100 mg was given per rectum at the conclusion of the ERCP. The PD stent was left in place at the conclusion of this procedure and had fallen out at follow-up abdominal radiograph about 2 weeks later (not shown). The patient did not experience PEP.
challenged by a meta-analysis conducted by Cennamo et al 78 in 2010 that included 6 RCTs (996 patients) that were designed to specifically assess the timing of precut papillotomies, which were performed in tertiary referral centers by skilled pancreaticobiliary endoscopists. Overall rates of cannulation were 90% in both the early precut and the standard approach groups. PEP occurred in only 2.5% of patients randomized to early precut, but in 5.3% of patients from the persistent standard approach group (OR, 0.47; 95% CI, 0.24-0.91). These results were supported by another meta-analysis published that same year by Gong et al. 79 In 2013, Swan et al 80 randomized 73 patients with difficult biliary cannulation to either NK papillotomy or to continued standard attempted cannulation. The main outcome measures were PEP and successful biliary cannulation. There was no difference in eventual cannulation success between the groups. However, 65% of the patients assigned to the continued standard cannulation group required cross-over to the NK papillotomy group. There was no significant difference in the development of PEP among patients in the early NK papillotomy group (20.5%) vs the standard cannulation group (17.6%; P ¼ 1.0). A 5F, plastic, single-pigtail stent was placed before NK papillotomy if the PD had been cannulated at least twice, but PD stenting was not pursued despite NK papillotomy if the PD was not accessed. Fiftynine percent of patients in the NK papillotomy arm received PD stents.
In some instances, neither biliary nor PD access will be possible, thus necessitating NK papillotomy. However, Cha et al 50 found in cases in which PD access was possible, that placing a PD stent to facilitate NK precut papillotomy and leaving the PD stent in place at the conclusion of the procedure reduced the frequency and severity of PEP.
These data suggest that when biliary access is not achieved by conventional ERCP techniques after a reasonable number or duration of attempts (although arbitrary, at least 5 attempts or 5-10 minutes) that early . (E) After biliary access, a completion biliary sphincterotomy was effected. (F) After sphincterotomy and dilation of a biliary stricture, copious drainage of dark bile was seen. The pancreas was not entered or opacified during this procedure, and PD stent placement was not attempted, but rectal indomethacin was given. PEP did not occur.
precutting is a logical next step that should not be associated with increased risk of PEP.
Pancreatic Sphincterotomy
As mentioned earlier, pancreatic sphincterotomy is a risk factor for PEP. 53 , 81 Lawrence et al 82 retrospectively examined the rates of PEP in patients undergoing NK and pull-type (traction) pancreatic sphincterotomy of the major papilla over a 13-year period. A total of 6.4% of patients who received NK pancreatic sphincterotomy suffered PEP as compared with 7.8% of patients in the pull-type sphincterotomy group, which was not a statistically significant difference. Although data are limited, freehand NK pancreatic sphincterotomy over a PD stent or traction pancreatic sphincterotomy with a wire in the main PD followed by PD stenting both are acceptable.
Large Papillary Balloon Dilation for Removal of Choledocholithiasis
Large papillary balloon dilation (LPBD) (from 12 to 20 mm) of the bile duct for removal of large bile duct stones can be performed without biliary sphincterotomy, or after a modest or complete biliary sphincterotomy. In a meta-analysis by Baron and Harewood, 83 PEP occurred more commonly in the papillary balloon dilation group (7.4%) as compared with a biliary sphincterotomy group (4.3%; P ¼ .05), although bleeding occurred less frequently in the balloon dilation group. In fact, a RCT of papillary balloon dilation (to 8 mm) vs biliary sphincterotomy was terminated early because of a significantly increased risk of pancreatitis, which in 2 cases led to death. 84 However, LPBD after biliary sphincterotomy has been shown to be quite efficacious at removing large bile duct stones with low rates of pancreatitis (2.2%). 85 As such, common practice is to perform at least a modest biliary sphincterotomy before LPBD for stone removal. Despite this more Western approach to LPBD, several Asian studies have not shown increased PEP rates with LPBD without prior biliary sphincterotomy. [86] [87] [88] [89] LPBD for removal of choledocholithiasis has become an important technique in the armamentarium of the therapeutic biliary endoscopist. At this time, we favor a modest biliary sphincterotomy before LPBD. If the PD was not accessed and there are no other risk factors for PEP, we do not routinely place PD stents after biliary sphincterotomy and LPBD. However, in patients with clinically relevant choledocholithiasis and untreatable coagulopathy or bleeding diatheses, which makes sphincterotomy relatively contraindicated owing to an increased risk of bleeding, LPBD over a prolonged dilation interval with or without PD stenting might be reasonable for bile duct stone clearance.
Please refer to the Supplementary Materials section for additional information on the use of contrast media, PD injection, and deep-enteroscopy-assisted ERCP pertaining to the prevention of PEP.
Summary and Recommendations
In summary, the strongest data concerning the use of pharmacotherapy in preventing PEP is for the use of rectal indomethacin in patients at increased risk for PEP. The effectiveness of using rectal indomethacin in average-risk patients remains less clear; however, its low cost, ease of administration, and favorable side-effect profile make it a reasonable preventative medication in this population as well. In terms of ERCP techniques, placement of a prophylactic PD stent when the PD has been manipulated or opacified or in patients at increased risk for PEP is a practice that is supported by numerous high-quality studies. Future studies are needed to directly compare the rates of PEP in patients who receive rectal indomethacin with those who receive a PD stent. Furthermore, prospective trials also are needed to determine if prophylactic PD stenting combined with rectal indomethacin might be superior to either therapy alone. 
Supplementary Material
Supplementary Materials
Other Hormones
Other biologically active hormones that have been used experimentally to prevent PEP include both calcitonin and glucagon. Both agents were selected on the basis of their ability to inhibit pancreatic secretion, 1, 2 however, neither has been proven to be effective. 3, 4 Overall, we do not presently advocate the use of somatostatin, octreotide, secretin, or other regulatory hormones for the purpose of reducing the risk of PEP.
Protease Inhibitors
The premature or inappropriate activation of trypsinogen has long been considered one of the inciting events in the development of acute pancreatitis. Therefore, the administration of an antiprotease to prevent the conversion of trypsinogen to trypsin during ERCP is conceptually attractive. 5 There are presently 3 lowmolecular-weight antiproteases available with efficacy against trypsin and other serine proteases: gabexate, ulinastatin, and nafamostat.
Gabexate first was synthesized in 1977 and has been used extensively in Japan and China for the management of severe acute pancreatitis. 6 Although previous RCTs have shown the effectiveness of gabexate in the prevention of PEP, [7] [8] [9] other studies [10] [11] [12] and subsequent data from meta-analyses 13, 14 have failed to show a consistent benefit.
Ulinastatin, a derivative of gabexate with a longer half-life, also showed promise in a multicenter Japanese trial including 406 patients undergoing ERCP. In this trial, the incidence of PEP was reduced significantly in patients receiving 150,000 U of IV ulinastatin 10 minutes before ERCP (2.9% vs 7.4%; P ¼ .041). 15 Despite this initial enthusiasm, subsequent trials with both similar and alternative dosing schedules have failed to show a consistent benefit. 16, 17 Nafamostat mesilate, an alternative agent, also has been shown to reduce the incidence of PEP compared with placebo when infused 1 hour before ERCP and continued afterward. 18 In a comparatively large RCT that included 608 patients, there was a marked reduction in PEP among patients who received nafamostat (13.0% vs 4.0%; P < .0001). A subgroup analysis from that study, however, showed that patients who were at high risk for PEP did not receive a benefit (14.6% vs 5.9%; P ¼ .108).
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A meta-analysis of trials involving all 3 protease inhibitors (along with nonsteroidal anti-inflammatory drugs) was published in 2013. This systematic review included 5 trials of gabexate, 6 trials of ulinastatin, and 5 trials of nafamostat from 1996 through 2012. This study included a total of 8211 patients involved in trials of antiproteases and suggested a reduction in PEP risk only with nafamostat (RR, 0.41; 95% CI, 0.28-0.59), but not with gabexate (RR, 0.64; 95% CI, 0.36-1.13), or ulinastatin (RR, 0.65; 95% CI, 0.33-1.30). 20 Despite these data, the use of protease inhibitors for PEP prophylaxis remains extremely limited outside of Asia. Given the earlier-described data and the low cost and relative simplicity of alternative options (eg, rectal indomethacin), we do not endorse the routine use of protease inhibitors for the prevention of PEP.
Other Medication Therapies
Serotonin (5-hydroxytryptamine) activates pancreatic enzyme secretion, and 5-hydroxytryptamine is associated with the development and aggravation of acute pancreatitis. 21 Risperidone is a 5-hydroxytryptamine 2A antagonist that has been hypothesized to have the potential to reduce the risk of PEP. Risperidone has been studied in 2 RCTs, alone 21 or in combination with ulinastatin. 22 Unfortunately, in both studies risperidone was not found to reduce the rates of PEP significantly.
Antioxidants also have been studied to test if they might have a role in preventing PEP. However, a metaanalysis of 3010 patients found that antioxidant supplementation showed no beneficial effect on the incidence and the severity of PEP. 23 
Type of Contrast Medium
The type of contrast injected into the PD also has been implicated in altering the risk of PEP, with lowosmolality, nonionic contrast agents such as iohexol being preferred. However, Sherman et al 24 compared rates of PEP in patients undergoing ERCP using lowosmolality, nonionic, iohexol (672 mOsm/kg H 2 O, Omnipaqe 300; GE Healthcare, Wauwatosa, WI) or highosmolality, ionic, diatrizoate sodium (1515 mOsm/kg H 2 O, Hypaque 50%; Amersham Health/GE Healthcare). They conducted an appropriately powered, double-blind, RCT that enrolled 690 patients but found no difference in the rates of PEP between patients who had ERCP performed using iohexol (7.5%) vs diatrizoate sodium (7.2%; P > .05). These investigators concluded that osmolality and ionicity do not appear to be major factors in provoking pancreatitis. Presently, there are no compelling data that suggest the type of contrast medium affects the occurrence of PEP.
Pancreatic Duct Injection
During ERCP, the pancreas can be exposed to several factors (mechanical, chemical, hydrostatic, enzymatic, microbiologic, allergic, and thermal) that may contribute to PEP. 25 When considering endoscopic retrograde pancreatography, likely factors that increase the risk of PEP include opacification of the entire PD, acinarization (owing to overly forceful injection of contrast), and possibly the number of PD injections.
Freeman et al 27 found in a prospective multicenter study on the risk factors of PEP that 1 or more contrast injections into the PD was a risk factor on adjusted multivariate analysis for PEP, with an OR of 2.7. In a prospective RCT comparing cannulation methods, Bailey et al 28 found on multivariate analysis that complete filling of the PD with contrast agent (OR, 3.5; P ¼ .02) was associated independently with PEP.
In general, complete filling of the PD should be avoided unless indicated for a specific diagnostic or therapeutic reason, so as to reduce the risk of PEP. Furthermore, minimizing the number of PD injections and the amount of contrast injected should help reduce the risk of PEP.
Deep-Enteroscopy-Assisted Endoscopic Retrograde Cholangiopancreatography
Single-balloon, double-balloon, and spiral enteroscopy platforms have been available for several years and enable ERCP in patients with altered gastroduodenal anatomy. 29 The rate of pancreatitis after balloonassisted enteroscopy without ERCP is less than 1%. 30, 31 In patients with an intact major papilla and without pancreas divisum, the rate of PEP after balloon-enteroscopy assisted ERCP ranges from 2.3% to 12.5%, [32] [33] [34] [35] which overall appears to be higher than for conventional ERCP. This increased risk of PEP is typically due to difficulty in selectively accessing the duct of interest using a forward-viewing enteroscope without an elevator.
In patients with Roux-en-Y gastric bypass anatomy who have particularly long Roux and afferent biliopancreatic limbs, 36 in those in whom complex or repeated pancreaticobiliary interventions are anticipated, or in patients who might be at increased risk for PEP, consideration should be given to performing ERCP using a duodenoscope passed through a gastrostomy placed in the gastric remnant. Typically, transgastric access to the excluded stomach is accomplished via laparoscopy, but endoscopic techniques have been described. 37 
